| Ticker | HLVX |
|---|---|
| ISIN | US43157M1027 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
HilleVax, Inc. opera en el sector Healthcare, industria Biotechnology.